Rebus Bio continues to expand its industry-leading spatial omics platform with revolutionary High-Plex technology
Rebus Biosystems Inc, (“Rebus Bio”, “Rebus”), a life sciences technology company backed by Illumina Ventures that creates revolutionary tools to advance research in space omics, today announced the acquisition intellectual property and associated analytical assets of EEL Transcriptomics AB, a private company focused on high-plex spatial transcriptomics with single-cell resolution. Terms of the agreement are not being disclosed.
The Rebus Esper ™ Spatial Omics Platform helps researchers better understand tissue biology, leading to advancements in neuroscience, cancer, infectious disease and immunology by enabling routine quantitative analysis of tens of millions of features cells in hundreds of thousands of cells. Performance of Electric FISH Improved (EEL) Analysis on the Esper platform enables spatial transcriptomics with single-cell resolution and has the potential to span over 5,000 genes.
“This acquisition delivers on our promise to continue to expand the platform and enable research from discovery to clinical research. The EEL test is highly synergistic with Rebus Esper’s synthetic aperture optics technology, delivering an unprecedented combination of plex number, throughput, resolution and sensitivity ”said Paul Sargeant, PhD, CEO of Rebus Biosystems. “By adding EEL to our assay library, Esper is now the only single-cell spatial transcriptomics technology on the market that will enable discovery through translational research. This will more efficiently produce improved and simple spatial workflows for a variety of sample types and disease areas on a single platform. ”
EEL Transcriptomics was co-founded by Sten Linnarsson, Ph.D., scientific advisor to Rebus and pioneer in the field of single-cell genomics and single-cell RNA sequencing, with graduate student Lars Borm, senior scientist, Simone Codeluppi , and other members of Dr Linnarsson’s lab at the Karolinska Institute in Sweden.
“With the addition of the EEL test to the Esper system, researchers can overcome well-known challenges in spatial multi-omics, allowing the analysis of large panels of genes over large fields of images in human brain samples,” Dr Linnarsson said. “Our EEL test already allows us to peer into the human brain in ways we have never been able to do before, revealing both the beauty of a healthy brain and the terrifying spatial complexity of human brain tumors.”
The EEL test will be available for use on the Esper system through early access during the first half of 2022 and commercially available in June 2022. This technology will be readily applicable to a wide range of sample types, including fresh frozen and formalin fixed samples. Paraffin coated (FFPE).
About Rebus Biosystems
Rebus Biosystems is a venture-funded, Silicon Valley-based life sciences technology company creating revolutionary tools to enable space omics research without compromise. The company’s first instrument, the Rebus Esper, is a fully integrated automated spatial omics platform that provides single-cell and single-cell quantitative data with subcellular resolution. Advanced imaging, on-system chemistry, and intuitive software have been combined to provide an end-to-end solution requiring minimal hands-on time. Rebus Biosystems provides all-inclusive assay kits to give researchers the resolution, scale and speed of the Rebus Esper for multiple applications. Find out more at www.rebusbio.com.